IPO Databook: Serina Therapeutics (SER US) - Aug 2026

87 Views26 Aug 2026 10:05

SUMMARY

Serina Therapeutics, Inc. is a clinical-stage biotechnology company developing wholly-owned drug product candidates for neurological diseases. Its POZ Platform™ technology improves polymeric drug conjugates.
Serina Therapeutics received FDA IND clearance for SER-252 in January 2026 and dosed the first patient in its Phase 1b trial in February 2026.
Management concluded substantial doubt exists about the Company’s ability to continue as a going concern within twelve months.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream